MedTrace Logo

Clinical Study of Manpixiao in the Treatment of Chronic Atrophic Gastritis

NCT05493124 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2022-08-09

No results posted yet for this study

Summary

To explore the efficacy and safety of "Manpixiao" in the treatment of Chronic Atrophic Gastritis.

Conditions

  • Chronic Atrophic Gastritis

Interventions

DRUG

Manpixiao

A traditional Chinese medicine composition

DRUG

Active comparator

Other drugs that may have therapeutic effects

Sponsors & Collaborators

  • Beijing University of Chinese Medicine

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05493124 on ClinicalTrials.gov